Cargando…

Quality of antibiotic prescribing for pediatric community-acquired Pneumonia in outpatient care

BACKGROUND: Antibiotics remain the primary treatment for community acquired pneumonia (CAP), however rising rates of antimicrobial resistance may jeopardize their future efficacy. With higher rates of disease reported in the youngest populations, effective treatment courses for pediatric pneumonia a...

Descripción completa

Detalles Bibliográficos
Autores principales: Saatchi, Ariana, Haverkate, Manon R., Reid, Jennifer N., Shariff, Salimah Z., Povitz, Marcus, Patrick, David M., Silverman, Michael, Morris, Andrew M., McCormack, James, Marra, Fawziah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612244/
https://www.ncbi.nlm.nih.gov/pubmed/37898747
http://dx.doi.org/10.1186/s12887-023-04355-w
_version_ 1785128659774865408
author Saatchi, Ariana
Haverkate, Manon R.
Reid, Jennifer N.
Shariff, Salimah Z.
Povitz, Marcus
Patrick, David M.
Silverman, Michael
Morris, Andrew M.
McCormack, James
Marra, Fawziah
author_facet Saatchi, Ariana
Haverkate, Manon R.
Reid, Jennifer N.
Shariff, Salimah Z.
Povitz, Marcus
Patrick, David M.
Silverman, Michael
Morris, Andrew M.
McCormack, James
Marra, Fawziah
author_sort Saatchi, Ariana
collection PubMed
description BACKGROUND: Antibiotics remain the primary treatment for community acquired pneumonia (CAP), however rising rates of antimicrobial resistance may jeopardize their future efficacy. With higher rates of disease reported in the youngest populations, effective treatment courses for pediatric pneumonia are of paramount importance. This study is the first to examine the quality of pediatric antibiotic use by agent, dose and duration. METHODS: A retrospective cohort study included all outpatient/primary care physician visits for pediatric CAP (aged < 19 years) between January 1 2014 to December 31 2018. Relevant practice guidelines were identified, and treatment recommendations extracted. Amoxicillin was the primary first-line agent for pediatric CAP. Categories of prescribing included: guideline adherent, effective but unnecessary (excess dose and/or duration), under treatment (insufficient dose and/or duration), and not recommended. Proportions of attributable-antibiotic use were examined by prescribing category, and then stratified by age and sex. RESULT(S): A total of 42,452 episodes of pediatric CAP were identified. Of those, 31,347 (76%) resulted in an antibiotic prescription. Amoxicillin accounted for 51% of all prescriptions. Overall, 27% of prescribing was fully guideline adherent, 19% effective but unnecessary, 10% under treatment, and 44% not recommended by agent. Excessive duration was the hallmark of effective but unnecessary prescribing (97%) Macrolides accounted for the majority on non-first line agent use, with only 32% of not recommended prescribing preceded by a previous course of antibiotics. CONCLUSION(S): This study is the first in Canada to examine prescribing quality for pediatric CAP by agent, dose and duration. Utilizing first-line agents, and shorter-course treatments are targets for stewardship. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-023-04355-w.
format Online
Article
Text
id pubmed-10612244
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106122442023-10-29 Quality of antibiotic prescribing for pediatric community-acquired Pneumonia in outpatient care Saatchi, Ariana Haverkate, Manon R. Reid, Jennifer N. Shariff, Salimah Z. Povitz, Marcus Patrick, David M. Silverman, Michael Morris, Andrew M. McCormack, James Marra, Fawziah BMC Pediatr Research BACKGROUND: Antibiotics remain the primary treatment for community acquired pneumonia (CAP), however rising rates of antimicrobial resistance may jeopardize their future efficacy. With higher rates of disease reported in the youngest populations, effective treatment courses for pediatric pneumonia are of paramount importance. This study is the first to examine the quality of pediatric antibiotic use by agent, dose and duration. METHODS: A retrospective cohort study included all outpatient/primary care physician visits for pediatric CAP (aged < 19 years) between January 1 2014 to December 31 2018. Relevant practice guidelines were identified, and treatment recommendations extracted. Amoxicillin was the primary first-line agent for pediatric CAP. Categories of prescribing included: guideline adherent, effective but unnecessary (excess dose and/or duration), under treatment (insufficient dose and/or duration), and not recommended. Proportions of attributable-antibiotic use were examined by prescribing category, and then stratified by age and sex. RESULT(S): A total of 42,452 episodes of pediatric CAP were identified. Of those, 31,347 (76%) resulted in an antibiotic prescription. Amoxicillin accounted for 51% of all prescriptions. Overall, 27% of prescribing was fully guideline adherent, 19% effective but unnecessary, 10% under treatment, and 44% not recommended by agent. Excessive duration was the hallmark of effective but unnecessary prescribing (97%) Macrolides accounted for the majority on non-first line agent use, with only 32% of not recommended prescribing preceded by a previous course of antibiotics. CONCLUSION(S): This study is the first in Canada to examine prescribing quality for pediatric CAP by agent, dose and duration. Utilizing first-line agents, and shorter-course treatments are targets for stewardship. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-023-04355-w. BioMed Central 2023-10-28 /pmc/articles/PMC10612244/ /pubmed/37898747 http://dx.doi.org/10.1186/s12887-023-04355-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Saatchi, Ariana
Haverkate, Manon R.
Reid, Jennifer N.
Shariff, Salimah Z.
Povitz, Marcus
Patrick, David M.
Silverman, Michael
Morris, Andrew M.
McCormack, James
Marra, Fawziah
Quality of antibiotic prescribing for pediatric community-acquired Pneumonia in outpatient care
title Quality of antibiotic prescribing for pediatric community-acquired Pneumonia in outpatient care
title_full Quality of antibiotic prescribing for pediatric community-acquired Pneumonia in outpatient care
title_fullStr Quality of antibiotic prescribing for pediatric community-acquired Pneumonia in outpatient care
title_full_unstemmed Quality of antibiotic prescribing for pediatric community-acquired Pneumonia in outpatient care
title_short Quality of antibiotic prescribing for pediatric community-acquired Pneumonia in outpatient care
title_sort quality of antibiotic prescribing for pediatric community-acquired pneumonia in outpatient care
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612244/
https://www.ncbi.nlm.nih.gov/pubmed/37898747
http://dx.doi.org/10.1186/s12887-023-04355-w
work_keys_str_mv AT saatchiariana qualityofantibioticprescribingforpediatriccommunityacquiredpneumoniainoutpatientcare
AT haverkatemanonr qualityofantibioticprescribingforpediatriccommunityacquiredpneumoniainoutpatientcare
AT reidjennifern qualityofantibioticprescribingforpediatriccommunityacquiredpneumoniainoutpatientcare
AT shariffsalimahz qualityofantibioticprescribingforpediatriccommunityacquiredpneumoniainoutpatientcare
AT povitzmarcus qualityofantibioticprescribingforpediatriccommunityacquiredpneumoniainoutpatientcare
AT patrickdavidm qualityofantibioticprescribingforpediatriccommunityacquiredpneumoniainoutpatientcare
AT silvermanmichael qualityofantibioticprescribingforpediatriccommunityacquiredpneumoniainoutpatientcare
AT morrisandrewm qualityofantibioticprescribingforpediatriccommunityacquiredpneumoniainoutpatientcare
AT mccormackjames qualityofantibioticprescribingforpediatriccommunityacquiredpneumoniainoutpatientcare
AT marrafawziah qualityofantibioticprescribingforpediatriccommunityacquiredpneumoniainoutpatientcare